**Supplement 2: Responding to Public Comments**

The Colorado Department of Health Care Policy & Financing (HCPF) submitted two comments on CMS information collection regarding the Medicaid Drug Use Review (DUR) Program, CMS-R-153 as published in the Federal Register at 86 FR 53060 on September 24, 2021. Comments received referenced an oversight on the FFS DUR survey. We appreciate the comments and agree with the assessment. There are no expected changes on any requirements, burden estimates, information collection/reporting instruments or guidance documents.

**Comment 1:** Crosswalk-FFS annual Report 2021 Final document: Consider if revision is needed related to the specific drug categories listed in the questions. For example, question 5 appears to be related to antidepressant drugs, but sub-question 5c asks about stimulants. This occurs similarly for questions 6 and 7.

CMS Response: We agree and would like to thank you for identifying this oversight.

Action(s) Taken: The Crosswalk-FFS annual Report 2021 Final document and FFS DUR Survey have been updated.

**Comment 2**: Since stimulant medications are not identified in the main question categories (i.e. question 5 for antidepressants, question 6 for mood stabilizers, and question 7 for antianxiety for sedatives), HCPF requests clarification regarding whether stimulant medications were intended to be included for reporting as part of this questions set.

CMS Response: We agree and would like to thank you for identifying this oversight.

Action(s) Taken: The Crosswalk-FFS annual Report 2021 Final document and FFS DUR Survey have been updated.